Other · developed by Rigel Pharmaceuticals
R348 is an ophthalmic solution tested at several concentrations (0.2%, 0.5%, 1.0%) in single and multiple ascending dose studies, and at 0.2% dosed twice daily. It is studied in keratoconjunctivitis sicca and chronic graft-versus-host disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02040623 | Phase 2 | Chronic Graft-versus-host Disease | Completed | RIGL |
| NCT01733992 | Phase 1 | Keratoconjunctivitis Sicca | Completed | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Graft-versus-host DiseaseKeratoconjunctivitis Sicca
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →